WO2022210487A1 - 抗原に特異的な受容体を発現する免疫細胞の製造方法 - Google Patents

抗原に特異的な受容体を発現する免疫細胞の製造方法 Download PDF

Info

Publication number
WO2022210487A1
WO2022210487A1 PCT/JP2022/014872 JP2022014872W WO2022210487A1 WO 2022210487 A1 WO2022210487 A1 WO 2022210487A1 JP 2022014872 W JP2022014872 W JP 2022014872W WO 2022210487 A1 WO2022210487 A1 WO 2022210487A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antigen
immune cells
immune
cell
Prior art date
Application number
PCT/JP2022/014872
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
いづみ 槇
幸子 岡本
舞子 杉崎
泰典 天石
佳典 田中
圭一朗 三原
Original Assignee
タカラバイオ株式会社
学校法人藤田学園
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タカラバイオ株式会社, 学校法人藤田学園 filed Critical タカラバイオ株式会社
Priority to JP2023511233A priority Critical patent/JPWO2022210487A1/ja
Publication of WO2022210487A1 publication Critical patent/WO2022210487A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Definitions

  • the present invention provides a method for producing immune cells expressing receptors specific to antigens present in both immune cells and target cells, and a method for producing immune cells that express antigen-specific receptors present in both immune cells and target cells, It relates to a method for producing a pharmaceutical composition comprising the step of obtaining immune cells that express the receptor.
  • a nucleic acid encoding a chimeric antigen receptor (CAR) that binds to a specific antigen present on the surface of tumor cells, or a T cell receptor (TCR) gene that recognizes tumor cells is used.
  • CAR chimeric antigen receptor
  • TCR T cell receptor
  • Patent Document 1 a method was recently developed to inactivate genes involved in antigen expression or presentation present on both the surface of T cells and the surface of target cells, followed by expression of CAR.
  • the present inventors have made intensive studies to solve the above problems, and found that immune cells into which nucleic acids encoding antigen-specific receptors present in both immune cells and target cells have been introduced into immune cells
  • the inventors have found that the antigen can be produced by suppressing the expression of the antigen in the introduced immune cells with siRNA and culturing the immune cells in a medium containing a kinase inhibitor, thereby completing the present invention.
  • [1] A method for producing immune cells that express antigen-specific receptors present in both immune cells and target cells, the method comprising the following steps in random order: (a) introducing into an immune cell a nucleic acid encoding a receptor specific for said antigen; (b) culturing immune cells in a medium containing a kinase inhibitor; and (c) suppressing expression of said antigen in immune cells; [2] The method of [1], wherein the immune cells are T cells or NK cells; [3] The method of [1], wherein the antigen is present on both the surface of normal immune cells and the surface of target cells.
  • the production of immune cells expressing antigen-specific receptors present on both immune cells and target cells, and the methods for producing antigen-specific receptors present on both immune cells and target cells Methods of making pharmaceutical compositions comprising immune cells expressing immune cells are provided.
  • the immune cells obtained by the production method of the present invention have a low expression rate of exhaustion markers, a high naive cell rate, and high cytotoxic activity.
  • FIG. 3 is a diagram showing the expression level of the CD38 gene with respect to the virus copy number.
  • FIG. 3 is a diagram showing the positive rate of PD-1 expression with respect to virus copy number.
  • FIG. 4 shows cell counts and cell viability.
  • FIG. 3 is a diagram showing the positive rate of PD-1 expression with respect to virus copy number.
  • FIG. 10 is a diagram showing the TIM-3 expression positive rate with respect to the virus copy number.
  • FIG. 4 is a diagram showing the positive rate of LAG-3 expression with respect to virus copy number.
  • FIG. 10 is a graph showing the naive cell rate with respect to virus copy number.
  • FIG. 4 is a diagram showing the cell number of Daudi cells;
  • immune cells refers to cells in general that are involved in immune function in vivo, including neutrophils, macrophages, lymphocytes ⁇ B cells and T cells>, natural killer (NK) cells, plasma A cell etc. are illustrated. Of these, T cells and NK cells are preferred for the present invention.
  • immune cells as used herein also includes "precursor cells of immune cells” that have the ability to differentiate into the aforementioned immune cells.
  • T cells are also called T lymphocytes, and mean cells derived from the thymus among lymphocytes involved in immune responses. T cells include helper T cells, suppressor T cells, regulatory T cells, cytotoxic T cells (CTLs), naive T cells, memory T cells, ⁇ T cells expressing ⁇ and ⁇ chain TCRs, ⁇ chains and ⁇ T cells expressing TCRs of the ⁇ chain.
  • CTLs cytotoxic T cells
  • naive T cells memory T cells
  • ⁇ T cells expressing ⁇ and ⁇ chain TCRs ⁇ chains and ⁇ T cells expressing TCRs of the ⁇ chain.
  • T cells capable of differentiating into T cells and “T cells or cell populations containing cells capable of differentiating into T cells” can also be used in the present invention.
  • Cells that can differentiate into T cells are not particularly limited as long as they are cells that differentiate into T cells in vivo or by artificial stimulation.
  • the "cell population containing T cells or cells capable of differentiating into T cells” includes blood (peripheral blood, umbilical cord blood, etc.), bone marrow fluid, and peripheral blood collected, isolated, purified, and induced therefrom.
  • Cell populations including nuclear cells (PBMC), hematopoietic cells, hematopoietic stem cells, cord blood mononuclear cells and the like are exemplified.
  • PBMC nuclear cells
  • hematopoietic cells hematopoietic stem cells
  • cord blood mononuclear cells and the like are exemplified.
  • Various cell populations derived from blood lineage cells containing T cells can also be used in the present invention. These cells may be activated in vivo or ex vivo by cytokines such as anti-CD3 antibodies and IL-2. These cells can be either collected from a living body or obtained through in vitro culture, for example, a T cell population obtained from a living body as it is or cryopreserved
  • NK cells are cytotoxic cells differentiated from hematopoietic stem cells via lymphoid stem cells, and express CD16, CD56, and CD57 on their surface. NK cells recognize cells that do not express MHC class I antigens and cells bound with antibody molecules as non-self, and directly damage them. NK cells can be prepared in vitro, for example, using PBMC as a starting material and culturing them in the presence of OK432 or other inducers.
  • the immune cells obtained by the present invention are provided with receptors having specificity for antigens known to be commonly expressed by target cells and immune cells or present on the surface of said immune cells.
  • the phrase "known to be present” refers to the presence of an antigen in vivo, particularly on the surface of immune cells in the blood or on the surface of immune cells cultured in vitro. It means that it is not always found. In any event, the use of the methods of the present invention results in reduced antigen expression in immune cells, thereby preventing immune cells expressing the receptor from attacking themselves.
  • target cell means a cell that is desired to be reduced or eliminated in a patient, and is exemplified by tumor cells and pathogen-infected cells. Although not particularly limited, it is preferably a tumor cell, more preferably a B-cell leukemia cell, or a solid tumor cell.
  • the term "antigen” means a biomolecule such as a protein or an immunological fragment thereof, and is a substance that binds to an antibody or an antigen receptor on an immune cell and induces an immune response.
  • an antigen exists on the surface of a cell, the cell will be removed from the body by the action of antibodies and lymphocytes. Normally, antigens originate from foreign pathogens such as bacteria and viruses, and heterologous proteins that enter the body through artificial injections. an immune response occurs.
  • antigens recognized by receptors encoded by nucleic acids introduced into immune cells are present in both immune cells and target cells. Furthermore, in one aspect of the present invention, the antigen is assumed to exist on the surface of normal immune cells. Examples of antigens include CD38, CD4 and CD7, preferably CD38.
  • the CD38 protein is a marker for HIV infection, leukemia, myeloma, solid tumors, type II diabetes, and bone metabolism, as well as several other genetically determined conditions.
  • CD38 protein is used as a prognostic marker for leukemia (Ibrahim, S. et al. 2001, Blood 98: 181-186).
  • the term "receptor” refers to an antigen-specific receptor. Preferably, it is a receptor capable of endowing immune cells with the property of recognizing and/or damaging target cells. Examples of such receptors include CAR and TCR.
  • CAR is a fusion protein comprising an antigen-binding extracellular domain (hereinafter referred to as an antigen-binding domain), a transmembrane domain derived from a polypeptide different from the antigen-binding domain, and at least one intracellular domain.
  • CARs are sometimes called “chimeric receptors,” “T-bodies,” and “chimeric immune receptors (CIRs).”
  • domain refers to a region within a polypeptide that folds into a specific structure independently of other regions.
  • Antigen-binding domain means any oligopeptide or polypeptide that can bind to an antigen.
  • antigen-binding domains include antigen-binding sites derived from antibodies, such as Fab' fragments, Fab fragments, Fv fragments, etc., but single-chain variable region fragments (scFv) are preferred for the present invention.
  • scFv refers to an antibody-derived single-chain polypeptide that retains antigen-binding ability. Examples thereof include polypeptides formed by recombinant DNA technology, in which the Fv region of an immunoglobulin heavy chain (H chain) and the Fv region of a light chain (L chain) are linked via a spacer sequence.
  • Intracellular domain means any oligopeptide or polypeptide known to function as a domain that transmits a signal that activates or inhibits a biological process within a cell.
  • the structure of a typical CAR consists of an scFv, a transmembrane domain, and an intracellular domain that activates cells.
  • Transmembrane domains derived from the TCR complex CD3 ⁇ , CD28, CD8 ⁇ , etc. are known.
  • the intracellular domain the intracellular domain of CD3 ⁇ is preferably used.
  • a CAR with such a configuration is called a first generation CAR.
  • CAR-expressing T cells directly recognize surface antigens of tumor cells independently of the expression of major histocompatibility antigen class I on tumor cells, and simultaneously activate T cells themselves. , can efficiently kill tumor cells.
  • T-cell co-stimulatory molecules As co-stimulatory molecules for T cells, CD28, the intracellular domain of CD137 (4-1BB) or CD134 (OX40), which is a tumor necrosis factor (TNF) receptor superfamily, the intracellular domain of interleukin receptors and modifications thereof glucocorticoid-induced tumor necrosis factor receptor (GITR) intracellular domain and the like are preferably used.
  • CD137 4-1BB
  • CD134 which is a tumor necrosis factor (TNF) receptor superfamily
  • GITR glucocorticoid-induced tumor necrosis factor receptor
  • nucleic acid constructs of the invention can contain any CAR-encoding sequence as the desired gene sequence.
  • TCR is responsible for the antigen recognition function of T cells, and is composed of polypeptides such as ⁇ -chain, ⁇ -chain, ⁇ -chain, and ⁇ -chain.
  • polypeptides such as ⁇ -chain, ⁇ -chain, ⁇ -chain, and ⁇ -chain.
  • heterodimers of TCR ⁇ chain (TCR ⁇ ) and TCR ⁇ chain (TCR ⁇ ) or heterodimers of ⁇ chain and ⁇ chain are used as auxiliary molecules in the CD3 complex ( ⁇ , ⁇ , ⁇ , ⁇ ), together with CD4 or CD8, etc., form the TCR.
  • TCR recognizes peptides (antigen epitopes) presented by target cells (phagocytic cells, virus-infected cells, cancer cells, etc.) via the major histocompatibility complex (MHC) in vivo, and target cells Responsible for the function of making an immune response against Human MHC is also referred to as the human histocompatibility leukocyte antigen (HLA) system.
  • HLA is classified into class I and class II. Class I includes HLA-A, B, C, E, F, G, H, and J. Class II includes HLA-DR, DQ, and DP. included.
  • HLA like TCR, is also formed by a complex of ⁇ and ⁇ chains, and presents antigenic epitopes on the cell surface via these chains.
  • HLA class I is present in almost all cells in the body and presents antigenic epitopes approximately nine amino acid residues long.
  • T cells such as CTL
  • TCR TCR specific to the antigen epitope
  • HLA-restricted refers to TCRs, as well as T cells expressing such TCRs, or antigen-HLA complexes presented by various peptides. , cells and the like. Binding of the TCR to the antigen-epitope-HLA complex results in an immune response, exemplified by the secretion of cytokines (interferon- ⁇ , TNF- ⁇ , IL-2, etc.) by CD8+ T cells.
  • cytokines interferon- ⁇ , TNF- ⁇ , IL-2, etc.
  • Binding of TCRs to antigen-epitope-HLA complexes can be measured indirectly by measuring secretion of the cytokines described above. Further, by detecting the binding of TCR to a complex of HLA (or a peptide fragment thereof) having a label such as green fluorescent protein (GFP) and an antigen epitope, the binding of TCR and antigen-HLA can be detected. It is directly measurable. Alternatively, known optical detection means utilizing the effect of light emission and extinction due to the proximity of two or more molecules can also be used.
  • GFP green fluorescent protein
  • Method for producing immune cells of the present invention (a) Step of introducing a nucleic acid encoding an antigen-specific receptor into immune cells
  • the method for producing immune cells of the present invention comprises antigen-specific receptors. into immune cells. The process is typically performed ex vivo.
  • the method of the present invention can use immune cells derived from mammals, such as humans, or immune cells derived from non-human mammals such as monkeys, mice, rats, pigs, cows, and dogs.
  • the immune cells used in the method of the present invention are not particularly limited, and any immune cells can be used.
  • cells collected, isolated, purified, or induced from blood peripheral blood mononuclear cells (PBMC), T cells, T cell progenitor cells (hematopoietic stem cells, lymphocyte progenitor cells, etc.), or cell populations containing these.
  • PBMC peripheral blood mononuclear cells
  • T cells T cell progenitor cells
  • lymphocyte progenitor cells hematopoietic stem cells, lymphocyte progenitor cells, etc.
  • T cells include CD8 positive T cells, CD4 positive T cells, regulatory T cells, cytotoxic T cells, or tumor infiltrating lymphocytes.
  • NK cells and their progenitor cells are also suitable as hosts for expressing antigen-specific receptors.
  • Cell populations containing T cells and T cell progenitor cells include PBMCs.
  • the above-mentioned cells may be those collected from living organisms, those obtained by expanding culture thereof, or those established as cell lines. When it is desired to transplant cells expressing a receptor specific to the manufactured antigen or cells differentiated from such cells into living organisms, the nucleic acid is transferred to the living organism itself or cells collected from the same kind of living organism. It is preferable to introduce
  • nucleic acids encoding antigen-specific receptors into immune cells can be carried out by known methods.
  • liposomes and WO 96/10038, WO 97/18185, WO 97/25329, WO 97/30170 and WO 97/31934 can be used to introduce nucleic acids encoding antigen-specific receptors into immune cells using condensing agents such as cationic lipids. can.
  • nucleic acids encoding antigen-specific receptors can be introduced into immune cells by calcium phosphate transfection, DEAE-dextran, electroporation, particle bombardment.
  • Nucleic acids encoding antigen-specific receptors can be loaded into appropriate vectors and introduced into immune cells.
  • vectors plasmid vectors (including episomal vectors), viral vectors (retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, etc.) and other known vectors can be used.
  • an expression control sequence promoter, terminator, enhancer, etc.
  • Viral vectors can infect cells and introduce nucleic acids retained in the viral genome. Methods for producing viral vectors as infectious particles are also well known to those skilled in the art. For example, when using a retroviral vector (including a lentiviral vector), suitable packaging cells are selected based on the LTR sequence and packaging signal sequence possessed by the vector, and used to prepare retroviral particles. can be prepared and carried out. For example, PG13 (ATCC CRL-10686), PA317 (ATCC CRL-9078), GP + E-86 and GP + envAm-12 (US Patent No. 5,278,056), Psi-Crip [Proceedings of the National Academy of Sciences, Volume 85, 6460-6464 (1988)].
  • Retroviral particles can also be produced using 293 cells and 293T cells, which have high transfection efficiency. Retroviral vectors based on many types of retroviruses and packaging cells that can be used for packaging the vectors are widely available commercially from various companies. Also, many reagents and kits for producing adenovirus vectors and AAV vectors are commercially available.
  • retroviral vectors and lentiviral vectors are suitable for introducing nucleic acids encoding antigen-specific receptors into immune cells.
  • Methods for viral transduction are well known in the art (Waither et al. (2000) Viral Vectors for Gene Transfer. Drugs. 60(2):249-271). Integrating viral vectors allow stable integration of polynucleotides into the cellular genome and long-term expression of antigen-specific receptors.
  • a functional substance that improves the introduction efficiency can be used [e.g., International Publication No. 95/26200, International Publication No. 00/ 01836 pamphlet (both incorporated herein by reference)].
  • Substances that improve transduction efficiency include substances that have activity to bind to viral vectors, such as fibronectin or fibronectin fragments.
  • a fibronectin fragment having a heparin-binding site such as a fragment commercially available as RetroNectin (registered trademark, CH-296, manufactured by Takara Bio Inc.) can be used.
  • RetroNectin registered trademark, CH-296, manufactured by Takara Bio Inc.
  • polybrene, fibroblast growth factor, type V collagen, polylysine, or DEAE-dextran which are synthetic polycations that have the effect of improving the efficiency of retroviral cell infection, can be used.
  • the functional substance is immobilized on an appropriate solid phase, such as a container (plate, petri dish, flask, bag, etc.) or a carrier (microbeads, etc.) used for cell culture.
  • an appropriate solid phase such as a container (plate, petri dish, flask, bag, etc.) or a carrier (microbeads, etc.) used for cell culture.
  • Nucleic acids introduced into immune cells using retroviral vectors are integrated into the chromosomes of the immune cells.
  • methods for integrating nucleic acids onto chromosomes include methods using transposons (PiggyBac, etc.) and methods using genome editing technology (CRISPR/Cas9, TALEN, etc.).
  • Step of culturing immune cells in a medium containing a kinase inhibitor The method for producing immune cells of the present invention is characterized by including a step of culturing immune cells in a medium containing a kinase inhibitor. do.
  • the conditions for culturing immune cells in the medium containing the kinase inhibitor are not particularly limited, and conditions commonly used for cell culture can be used.
  • culture can be performed using plates, flasks, cell culture bags, large culture tanks, etc. under conditions such as 37° C. and 5% CO 2 .
  • operations such as adding fresh medium to the cell culture solution to dilute it at appropriate time intervals, exchanging the medium, and exchanging the cell culture equipment can be performed.
  • the medium used for culture is not particularly limited, either, and a serum-containing medium, serum-free medium, xeno-free medium, or the like having a general composition may be used.
  • kinase inhibitor refers to a drug that inhibits kinase activity, and inhibits kinases such as low-molecular-weight compounds, polypeptides, proteins, nucleic acids (siRNA, miRNA, aptamers, etc.), and other macromolecular compounds. Including drugs.
  • tyrosine kinase inhibitors TKIs
  • a tyrosine kinase is an enzyme that phosphorylates the hydroxyl groups on the side chains of tyrosine residues in proteins, and is a type of protein kinase.
  • a protein kinase transfers phosphate from ATP to a substrate protein and phosphorylates it, thereby changing the three-dimensional structure of the substrate protein and regulating its activity, thereby regulating cell functions.
  • Serine/threonine kinases have long been known as representative intracellular protein kinases, but various tyrosine kinases have been reported since it was discovered that retroviral oncogene products act as tyrosine kinases. . Since these tyrosine kinases were cell growth factor receptors and oncogene products, they are the subject of research on cell signaling, cell proliferation and canceration.
  • tyrosine kinase inhibitors are exemplified by dasatinib, imatinib, nilotinib, sunitinib, pazopanib, quizartinib, crenolanib or sorafenib, preferably dasatinib.
  • Dasatinib is an antineoplastic agent (anti-cancer agent) developed by Bristol-Myers Squibb as a tyrosine kinase inhibitor, a molecularly targeted therapeutic drug that targets multiple tyrosine kinases including BCR-ABL. be.
  • the concentration of the tyrosine kinase inhibitor added to the medium used in this step is, for example, 5-200 nM, preferably 15-100 nM, more preferably 40-60 nM.
  • the tyrosine kinase inhibitor is added after the step of introducing the nucleic acid encoding the antigen-specific receptor (after the last introduction when introducing multiple times), for example, within 3 days, preferably 2 days. It is carried out within days, more preferably within 24 hours.
  • a tyrosine kinase inhibitor may be added immediately after introduction of a nucleic acid encoding an antigen-specific receptor into cells and culture may be initiated.
  • the culture time in the presence of the tyrosine kinase inhibitor is, for example, 1 to 15 days, preferably 2 to 10 days, more preferably 3 to 5 days. It is a matter of course to determine an appropriate culture time depending on the type. Also, the concentration of the tyrosine kinase inhibitor may be changed as appropriate during the culture time. Furthermore, after culturing the cells in the presence of the tyrosine kinase inhibitor, the cells may be cultured in medium without the tyrosine kinase inhibitor.
  • Step of Suppressing Antigen Expression in Immune Cells The method for producing immune cells of the present invention is characterized by including a step of suppressing antigen expression in immune cells.
  • suppression of expression refers to suppression of final production of a polypeptide by preventing transcription and/or translation from a gene encoding a polypeptide. This means that the volume will decrease. Therefore, even if the transcription reaction from the gene encoding the polypeptide is not suppressed, it is included in “suppression of expression” if the transcription product (mRNA) is rapidly degraded and the production of the polypeptide is suppressed.
  • a state in which the expression is suppressed is a state in which the expression level is reduced by 20% or more, 40% or more, 60% or more, or 80% or more compared to the case where the expression is not suppressed, or a state in which the expression level is reduced by 100%, that is, completely suppressed state.
  • the above "suppression of expression” is performed by knocking down the antigen gene using siRNA.
  • Knockdown of an antigen gene by siRNA is performed by introducing into cells a nucleic acid encoding the siRNA, that is, a siRNA-producing sequence.
  • An example of an siRNA generating sequence is a sequence from which RNA is transcribed that forms at least one stem-loop structure and is capable of inducing RNA interference in mammalian cells.
  • RNA interference in the present invention aims to selectively suppress the expression of specific endogenous genes that cells naturally express by introducing nucleic acids containing siRNA-producing sequences.
  • RNA interference is induced by siRNA annealed with an RNA molecule homologous to and complementary to the base sequence of mRNA transcribed from a gene whose expression is desired to be suppressed (hereinafter referred to as a target gene). .
  • the siRNA-generating sequence used in the present invention includes, for example, a sequence (sense sequence) homologous to a region of the mRNA transcribed from the target gene and a complementary sequence (antisense sequence) arranged in series. are placed in A single RNA strand transcribed from this siRNA-producing sequence forms a double-stranded structure by annealing the sense sequence and the antisense sequence within the molecule, and the formed double-stranded RNA portion is used as the stem region.
  • a stem-loop structure is formed with any sequence located between the sequence and the antisense sequence as the loop region.
  • siRNA is produced from this stem region by the action of RNase III (Dicer).
  • the chain length of the portion corresponding to the stem region in the siRNA generating sequence is, for example, 13 to 29 bases, preferably 15 to 25 bases, more preferably 19 to 25 bases.
  • the loop region may have any sequence, and a sequence of 1 to 30 nucleotides is exemplified, preferably a sequence of 1 to 25 nucleotides, more preferably 5 to 22 nucleotides.
  • the siRNA produced in cells according to the present invention is composed of RNA with a sequence that is homologous to the specific base sequence of the mRNA transcribed from the target gene and RNA with a sequence that is complementary to each other. It does not need to be completely homologous or complementary to the specific base sequence of mRNA. siRNA consisting of substantially homologous RNA and substantially complementary sequence RNA may be used as long as the function of suppressing the expression of the target gene is exhibited.
  • the siRNA generating sequence used in the present invention transcribes one type of siRNA targeting one type of gene, and also transcribes a plurality of siRNAs corresponding to the base sequences of different regions of one type of target gene.
  • the number of siRNAs generated from the siRNA-generating sequences used in the present invention is 1-10, 1-6, 1-4, multiple or several.
  • the present invention relates to the siRNA-generating sequences of the base sequences shown in SEQ ID NO: 8 and SEQ ID NO: 9, and nucleic acids in which either or both of these sequences are arranged so that siRNA is expressed in cells, which are described in the following examples. Provide constructs.
  • nucleic acid containing an siRNA-producing sequence into an immune cell can be performed in the same manner as for nucleic acids encoding antigen-specific receptors.
  • the present invention is not particularly limited, from the viewpoint of stably suppressing the expression of antigens in immune cells, retroviral vectors and lentiviral vectors that have the property of integrating introduced nucleic acids into chromosomes are used in cells. It is desirable to load nucleic acid containing an siRNA-producing sequence in such a configuration that siRNA is expressed therein and then introduce it into immune cells.
  • the timing of introducing the nucleic acid containing the siRNA generating sequence into the immune cells may be before, at the same time as, or after the step (a) of introducing the nucleic acid encoding the antigen-specific receptor.
  • introduction of a nucleic acid containing an siRNA-generating sequence into an immune cell is performed at the same time as step (a).
  • a vector carrying a nucleic acid encoding a specific receptor may be simultaneously introduced into an immune cell, or both the nucleic acid containing the siRNA-generating sequence and the nucleic acid encoding the antigen-specific receptor are carried in the same vector. , may be introduced into immune cells. That is, step (a) and step (c) may be performed in one step.
  • the steps (a) to (c) may be performed in any order, or two or more of the steps (a) to (c) may be performed simultaneously.
  • the present invention includes the step of obtaining immune cells expressing antigen-specific receptors present on both immune cells and target cells by the method of (1). , a method of making a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition containing, as an active ingredient, immune cells that express antigen-specific receptors present on both immune cells and target cells.
  • the pharmaceutical composition may further contain suitable excipients.
  • excipients include, for example, pharmaceutically acceptable excipients, various cell culture media, isotonic saline, and the like.
  • the disease to which the pharmaceutical composition is administered is not particularly limited as long as it is a disease that shows sensitivity to the immune cells.
  • Examples include cancer [blood cancer (leukemia), solid tumor, etc.], inflammatory disease /autoimmune diseases (asthma, eczema), infectious diseases caused by viruses such as hepatitis, influenza, HIV, bacteria, and fungi, such as tuberculosis, MRSA, VRE, and deep mycosis.
  • the pharmaceutical composition of the present invention can also be used for bone marrow transplantation, prevention of infectious diseases after irradiation, donor lymphocyte transfusion for the purpose of remission of recurrent leukemia, and the like.
  • the pharmaceutical compositions of the present invention can be administered by, but not limited to, parenteral administration, such as injection or infusion, intradermally, intramuscularly, subcutaneously, intraperitoneally, intranasally, intraarterially, intravenously, intratumorally, or It can be administered into afferent lymphatics and the like.
  • pMS3-MC described in International Publication No. 2013/051718 was prepared.
  • pMS3-MC has, in order from the 5′ end, MMLV (Moloney murine leukemia virus)-derived 5′ LTR (long terminal repeat), MMLV-derived SD (splice donor) sequence, MMLV-derived ⁇ (packaging signal) sequence, It is a retroviral vector plasmid having an SA (splice acceptor) sequence derived from the human EF1 ⁇ gene and a 3'LTR derived from MMLV, and the U3 region of the 3'LTR is replaced with a sequence derived from MSCV (mouse stem cell virus).
  • SA splice acceptor
  • a DNA fragment denoted as antiCD38-CAR in Fig. 1 was synthesized.
  • This DNA fragment contains a Kozak sequence (SEQ ID NO: 1), which is said to have the highest translation efficiency, at the 5' end, a CD8 ⁇ signal peptide (amino acid sequence: SEQ ID NO: 2), and an anti-CD38 monoclonal antibody that binds to the cancer antigen CD38.
  • VL amino acid sequence: SEQ ID NO: 3
  • linker sequence amino acid sequence: SEQ ID NO: 4
  • VH of anti-CD38 monoclonal antibody amino acid sequence: SEQ ID NO: 5
  • CD28 domain CD28-derived polypeptide containing transmembrane domain; It encodes one molecule of CAR containing amino acid sequence: SEQ ID NO: 6) and CD3 ⁇ intracellular domain (amino acid sequence: SEQ ID NO: 7) in order from the N-terminus.
  • This DNA fragment was inserted into pMS3-MC to generate pMS3-CD38-CAR.
  • the Kozak sequence is "K”
  • the CD8 ⁇ signal peptide is "SP”
  • the VL of the anti-CD38 monoclonal antibody is “anti-CD38 VL”
  • the linker sequence is "L”
  • the VH of the anti-CD38 monoclonal antibody is "anti -CD38 VH”
  • CD28 domain as "CD28”
  • CD3 ⁇ intracellular domain as “CD3 ⁇ ”
  • terminal repeat LTR
  • splice donor sequence as "SD”
  • splice acceptor sequence as "SA”
  • packaging signal sequence is displayed as " ⁇ ".
  • FIG. 2 shows a plasmid prepared by modifying pMS3-CD38-CAR. That is, sequences that generate two types of siRNA against the CD38 gene (SEQ ID NO: 8 and SEQ ID NO: 9) are inserted between the ⁇ sequence and SA sequence of pMS3-CD38-CAR to prepare pMS3-CD38-siRNA-CAR. did. Furthermore, the sequences encoding the anti-CD38 monoclonal antibodies VL and VH of pMS3-CD38-CAR were converted to VL and anti-CEA monoclonal antibodies that bind to the cancer antigen CEA (carcinoembryonic antigen), respectively, based on the description of Japanese Patent Application No. 2020-164927.
  • CEA cancer antigen
  • pMS3-CEA-CAR was created by replacing the VH-encoding sequence.
  • interleukin 2 receptor ⁇ chain is inserted between the CD28 domain and the CD3 ⁇ intracellular domain.
  • a portion of the intracellular domain (IL2R ⁇ ) (amino acid sequence: SEQ ID NO: 10) is inserted, and the amino acid sequence (LHMQ) in the CD3 ⁇ intracellular domain is replaced with a STAT3 binding motif (YRHQ) required for activation of STAT3 signaling.
  • pMS3-CD38-JS-CAR and pMS3-CD38-JS-siRNA-CAR were prepared by doing so.
  • IL2R ⁇ interleukin-2 receptor ⁇ chain
  • CD3 ⁇ intracellular domain amino acid sequence: SEQ ID NO: 11
  • YRHQ STAT3 binding motif
  • Example 2 Preparation of Retrovirus Solution Escherichia coli HST08 was transformed with each of the plasmids prepared in Example 1 to obtain transformants. Plasmid DNAs possessed by these transformants were each purified using NucleoBond Xtra Midi (manufactured by Macharei Nagel) and subjected to the following procedures as DNAs for transfection. 293T cells were transfected with the prepared DNA for transfection and pGP vector and pE-eco vector contained in Retrovirus Packaging Kit Eco (manufactured by Takara Bio Inc.). This operation was performed according to the product protocol of the kit.
  • a supernatant containing the ecotropic virus was obtained from each of the obtained transduced cells and filtered through a 0.45 ⁇ m filter (Milex HV, manufactured by Millipore). This supernatant was used to infect PG13 cells (ATCC CRL-10686) with ecotropic virus by a method using polybrene. The culture supernatant of the obtained cells was collected and filtered through a 0.45 ⁇ m filter to prepare each retrovirus solution, which was used in subsequent examples.
  • Example 3 Suppression of CD38 gene expression by siRNA Retronectin (Registered Trademark, manufactured by Takara Bio Inc.) was infected twice by a standard method to prepare PBMCs expressing each CAR. Furthermore, PBMCs were cultured under conditions of 37° C., 95% humidity and 5% CO 2 .
  • the composition of the medium is LymphoONE T-Cell Expansion Xeno containing 200 IU/mL Proleukin (IL-2) (manufactured by Nipro) and 0.6% (v/v) AB serum (manufactured by Access Biologicals).
  • - Free Medium manufactured by Takara Bio Inc.
  • cDNA was synthesized using PrimeScript RT reagent Kit (Perfect Real Time) (manufactured by Takara Bio Inc.).
  • real-time PCR was performed using TB Green Premix Ex Taq II (manufactured by Takara Bio Inc.) and a CD38 gene amplification primer set (SEQ ID NO: 12 and SEQ ID NO: 13) to measure the gene expression level. .
  • the relative expression level of the CD38 gene was calculated by measuring the expression level of the GAPDH gene, which is a housekeeping gene, using the primer set shown in SEQ ID NO: 14 and SEQ ID NO: 15. Furthermore, genomic DNA was extracted from the cells 7 days after the second virus infection using SimplePreagent for DNA (manufactured by Takara Bio Inc.), Provirus Copy Number Detection Primer Set, Human (manufactured by Takara Bio Inc.) and Cycleave PCR Core Kit. (manufactured by Takara Bio Inc.) was used to measure the retrovirus copy number integrated into the genome.
  • the vertical axis indicates the relative value of the expression level of the CD38 gene in the CD38-siRNA-CAR-introduced cells when the expression level of the CD38 gene in the CD38-CAR-introduced cells is set to 100.
  • CD38 gene expression was suppressed in CD38-siRNA-CAR-transfected cells compared to CD38-CAR-transfected cells.
  • Example 4 Increase in Exhaustion Marker by CD38-CAR Expression
  • a standard method using retronectin in which retroviral solutions for expressing CAR prepared in Example 2 were added to PBMCs isolated from human peripheral blood at various dilutions. to generate PBMCs expressing each CAR.
  • the number of retroviruses integrated into the genome of cells 3 days after the second virus infection was measured.
  • FIG. 4 shows the ratio of PD-1 positive cells to the copy numbers of CD38-CAR and CEA-CAR retroviruses. As shown in FIG. 4, the proportion of cells expressing the exhaustion marker PD-1 was increased in CD38-CAR-transfected cells compared to non-transfected cells (NGMC) and CEA-CAR-transfected cells.
  • NGMC non-transfected cells
  • Example 5 Increase in Cell Number and Cell Viability by siRNA and Kinase Inhibitor Retronectin was applied to PBMCs isolated from human peripheral blood at various dilutions of each CAR-expressing retrovirus solution prepared in Example 2.
  • Each CAR-expressing PBMC was generated by two rounds of infection using standard methods. After the second virus infection, each cell was divided into two halves, Dasatinib (manufactured by Cell Signaling Technology) was added to one half at a concentration of 50 nM, and Dasatinib was not added to the other half, and cultured for 4 days.
  • the retrovirus copy number was measured in the same manner as in Example 3, and the cell number and cell viability were measured.
  • Figure 5 shows the cell number and cell viability in CAR-introduced cells with a virus copy number of 1.5 to 1.8 copies/cell.
  • CD38-CAR-transfected cells and CD38-siRNA-CAR-transfected cells decreased in cell number and cell viability compared to NGMC.
  • the number of CD38-siRNA-CAR-introduced cells was greater than the number of CD38-CAR-introduced cells.
  • addition of Dasatinib restored the cell number and cell viability of CD38-CAR-introduced cells and CD38-siRNA-CAR-introduced cells to the same level as NGMC.
  • Example 6 Reduction of Exhaustion Markers by siRNA and Kinase Inhibitor PBMCs isolated from human peripheral blood were diluted with various dilutions of each CAR-expressing retrovirus solution prepared in Example 2, and retronectin was used as a standard method. method to generate PBMCs expressing each CAR.
  • Dasatinib manufactured by Cell Signaling Technology
  • retrovirus copy numbers integrated into the genome of cells cultured for 15 days after retrovirus infection were measured.
  • PE-labeled anti-Human CD279 (PD-1) antibody manufactured by Becton Dickinson
  • APC-Cy7-labeled anti-Human CD366 (Tim-3) antibody manufactured by BioLegend
  • PD-1 antibody manufactured by Becton Dickinson
  • Tim-3 antibody manufactured by BioLegend
  • PAG-3 antibody PerCP/Cyanine 5.5-labeled anti-Human CD223 (LAG-3) antibody
  • Figure 6 shows the ratio of PD-1 positive cells to the virus copy number
  • Figure 7 shows the ratio of Tim-3 positive cells to the virus copy number
  • Figure 8 shows the ratio of LAG-3 positive cells to the virus copy number.
  • the positive rate of each exhaustion marker was decreased in cells expressing siRNA against CD38 compared to cells not expressing siRNA.
  • addition of Dasatinib further decreased the positive rate of exhaustion markers. That is, the positive rate of exhaustion markers decreased most under the condition that Dasatinib was added to cells expressing siRNA against CD38.
  • Example 7 Increase in Naive Rate by siRNA and Kinase Inhibitor PBMCs isolated from human peripheral blood were added with various dilutions of each CAR-expressing retrovirus solution prepared in Example 2, and retronectin-based standard method to generate PBMCs expressing each CAR. Furthermore, under certain conditions, Dasatinib was added at a concentration of 50 nM after the second virus infection, and a biotin-labeled anti-mouse IgG antibody (manufactured by Jackson ImmunoResearch) was added to cells cultured for 15 days after retrovirus infection.
  • streptavidin-APC manufactured by BioLegend
  • PerCP/Cyanine5.5-labeled anti-Human CD8 antibody manufactured by Beckman Coulter
  • FITC-labeled anti-Human CD197 (CCR7) antibody manufactured by BioLegend
  • PE-labeled anti-Human CD45RA Cells were stained by adding an antibody (BioLegend).
  • the percentage of cells positive for CCR7 and CD45RA among cells positive for APC among PerCP/Cyanine5.5-positive cells was measured for the stained cells. That is, the proportion of CAR-positive cells among CD8-positive cells and naive cells was measured.
  • Figure 9 shows the ratio of naive cells to virus copy number.
  • addition of Dasatinib to CD38-CAR-transfected cells resulted in more naive cells.
  • the condition in which Dasatinib was added to the CD38-siRNA-CAR-introduced cells resulted in containing the largest number of naive cells.
  • Example 8 Maintenance of cytotoxic activity by siRNA and kinase inhibitor PBMCs isolated from human peripheral blood were diluted with various dilutions of each CAR-expressing retrovirus solution prepared in Example 2, and retronectin was used as a standard method.
  • Each CAR-expressing PBMC was prepared by infecting each CAR twice. After the second virus infection, each cell was divided into two halves, one of which was added with Dasatinib at a concentration of 50 nM, and the other of which was cultured for 7 days without Dasatinib. Seven days after the second virus infection, the cells were co-cultured with CD38-positive Daudi cells (National Institute of Biomedical Innovation, Health and Nutrition JCRB9071), and the number of Daudi cells was measured every 3 to 4 days. In addition, Daudi cells were added during cell number determination.
  • CD38-positive Daudi cells National Institute of Biomedical Innovation, Health and Nutrition JCRB9071
  • Fig. 10 shows the number of Daudi cells versus the number of days of co-culture. Until the 17th day, proliferation of Daudi cells was suppressed under all conditions except NGMC. However, on day 21, Daudi cells proliferated only in CD38-JS-CAR-introduced cells without the addition of Dasatinib. This result indicates that the cytotoxic activity of CAR-expressing cells is maintained by suppressing CD38 expression with siRNA and/or by adding Dasatinib.
  • the production of immune cells expressing antigen-specific receptors present on both immune cells and target cells and the methods for producing antigen-specific receptors present on both immune cells and target cells
  • Methods of making pharmaceutical compositions comprising immune cells expressing immune cells are provided.
  • the method of the present invention is particularly useful for medical applications.
  • SEQ ID NO:1 Kozak sequence
  • SEQ ID NO:2 CD8 alpha signal peptide
  • SEQ ID NO:3 anti-CD38 VL sequence
  • SEQ ID NO:4 linker sequence
  • SEQ ID NO:5 anti-CD38 VH sequence
  • SEQ ID NO:6 CD28 domains
  • SEQ ID NO:7 CD3 zeta intracellular domain
  • SEQ ID NO:8 CD38_siRNA_2
  • SEQ ID NO:10 IL2R beta domain
  • SEQ ID NO:11 CD3 zeta intracellular domain with STAT3-binding motif (YRHQ)
  • SEQ ID NO:14 GAPDH-Fw primer
  • SEQ ID NO:15 GAPDH-Rv primer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2022/014872 2021-03-29 2022-03-28 抗原に特異的な受容体を発現する免疫細胞の製造方法 WO2022210487A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023511233A JPWO2022210487A1 (enrdf_load_stackoverflow) 2021-03-29 2022-03-28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-054835 2021-03-29
JP2021054835 2021-03-29

Publications (1)

Publication Number Publication Date
WO2022210487A1 true WO2022210487A1 (ja) 2022-10-06

Family

ID=83459215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/014872 WO2022210487A1 (ja) 2021-03-29 2022-03-28 抗原に特異的な受容体を発現する免疫細胞の製造方法

Country Status (2)

Country Link
JP (1) JPWO2022210487A1 (enrdf_load_stackoverflow)
WO (1) WO2022210487A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119060951A (zh) * 2024-11-05 2024-12-03 星奕昂(上海)生物科技有限公司 一种高密度培养条件下提高nk细胞活率的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506636A (ja) * 2014-02-14 2017-03-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
JP2017532950A (ja) * 2014-07-15 2017-11-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法用の操作された細胞
JP2020515581A (ja) * 2017-03-31 2020-05-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
WO2020180243A1 (en) * 2019-03-01 2020-09-10 National University Of Singapore Engineered immune cells
JP2021505604A (ja) * 2017-12-07 2021-02-18 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506636A (ja) * 2014-02-14 2017-03-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
JP2017532950A (ja) * 2014-07-15 2017-11-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法用の操作された細胞
JP2020515581A (ja) * 2017-03-31 2020-05-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法
JP2021505604A (ja) * 2017-12-07 2021-02-18 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節
WO2020180243A1 (en) * 2019-03-01 2020-09-10 National University Of Singapore Engineered immune cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMAISHI YASUNORI, MAKI IZUMI, SUGIZAKI MAIKO, MIHARA KENICHIRO, OKAMOTO SACHIKO, MINENO JUNICHI: "103 Quality improvement of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and inhibition of tyrosine kinase", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL, LONDON, GB, vol. 9, no. Suppl 2, 1 November 2021 (2021-11-01) - 14 November 2021 (2021-11-14), GB , pages A113 - A113, XP055971735, ISSN: 2051-1426, DOI: 10.1136/jitc-2021-SITC2021.103 *
OKAMOTO SACHIKO, IZUMI MAKI, MAIKO SUGIZAKI, YASUNORI AMAISHI, KEICHIRO MIHARA, JUNICHI MINENO: "626. Combination of Silencing CD38 and Tyrosine Kinase Inhibitor Treatment Can Improve the Quality of CD38-JAK-STAT CAR-T Cells", MOLECULAR THERAPY, ELSEVIER INC., US, vol. 29, no. 4, Suppl. 1, 27 April 2021 (2021-04-27) - 14 May 2021 (2021-05-14), US , pages 303 - 304, XP055971729, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2021.04.019 *
YASUNORI AMAISHI, IZUMI MAKI, MAIKO SUGISAKI, KEIICHIRO MIHARA, SACHIKO OKAMOTO, JUNICHI MINENO: "P-14 Improving the quality of anti-CD38-JAK/STAT CAR-T cells by suppressing CD38 expression and combining kinase inhibitors", PROGRAM AND ABSTRACTS OF THE 25TH ANNUAL MEETING OF THE JAPANESE SOCIETY FOR CANCER IMMUNOLOGY; JULY 1-3, 2021, JAPANESE SOCIETY FOR CANCER IMMUNOLOGY, JP, vol. 25, 7 June 2021 (2021-06-07) - 3 July 2021 (2021-07-03), JP, pages 151, XP009539917 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119060951A (zh) * 2024-11-05 2024-12-03 星奕昂(上海)生物科技有限公司 一种高密度培养条件下提高nk细胞活率的方法

Also Published As

Publication number Publication date
JPWO2022210487A1 (enrdf_load_stackoverflow) 2022-10-06

Similar Documents

Publication Publication Date Title
US20240091256A1 (en) Genetic engineering of macrophages for immunotherapy
JP6709549B2 (ja) Ｔ細胞の機能増強方法
JP6877905B2 (ja) 細胞免疫療法のための方法および組成物
JP7604000B2 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
WO2020020194A1 (en) Gd2-based chimeric antigen receptor and application thereof
BR112021003305A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
US12186343B2 (en) Method and composition for treating tumors
JP2018504894A (ja) キメラ抗原受容体およびその使用方法
JP7233720B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
TW201734205A (zh) 表現免疫機能控制因子之免疫活性細胞及表現載體
CN113811604A (zh) Car-nk细胞的产生方法及其用途
JP5805089B2 (ja) 細胞集団の製造方法
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
JP2022513665A (ja) ナチュラルキラー細胞のエクスビボ増殖のための方法およびその使用方法
WO2011052638A1 (ja) サイトカイン誘導キラー細胞の製造方法
CN112204133A (zh) Car nk细胞
JP2018531022A6 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
WO2009139413A1 (ja) サイトカイン誘導キラー細胞含有細胞集団の製造方法
WO2011024791A1 (ja) レチノイン酸存在下でのｔ細胞集団の製造方法
WO2022210487A1 (ja) 抗原に特異的な受容体を発現する免疫細胞の製造方法
JP5485139B2 (ja) 遺伝子導入細胞の製造方法
CN115066248A (zh) 嵌合抗原受体树突状细胞(car-dc)及其制备和使用方法
US20250235478A1 (en) Chimeric antigen receptor modified regulatory t cells for treating cancer
EP4602171A1 (en) Transduction of gammadelta t cells with pseudotyped retroviral vectors
WO2023225512A2 (en) Methods for optimizing t cell immunotherapeutic effector and memory function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22780698

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023511233

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22780698

Country of ref document: EP

Kind code of ref document: A1